Phase 2 N=41 Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar
Squamous Cell Carcinoma
Primary: Response Rate — .35; .22 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=61 Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva
Stage III Vulvar Cancer · Stage IVB Vulvar Cancer · Vulvar Squamous Cell Carcinoma
Primary: Complete Clinical and Pathologic Response — 50 Percentage of Participants
N/A N=47 Ultrasonic Aspiration Versus CO2 Laser Ablation for the Treatment of Vulvar Intraepithelial Neoplasia
Vulvar Intraepithelial Neoplasia (VIN)
Primary: Number of Participants With Recurrence of Dysplasia — 5; 8 Participants
N/A N=12 The CO2RE® System for Vulvar Lichen Sclerosus
Vulvar Lichen Sclerosus
Primary: Average Scores for VLS Clinical Signs Present At Baseline, 3, 6 and 12 Months After the Last Treatment as Assessed by the Investigators — 1.85; 0.65; 0.65; 0.73 score on…
N/A N=8 Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
Vulvar Cancer
Primary: Percentage of Participants With Clinical and Histologic Remission — 75 % of participants
Phase 2 N=9 CC-10004 For The Treatment Of Vulvodynia
Vulvodynia
Primary: Global Response Assessment — 5 participants
Phase 2 N=33 Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) · Vulvar Dysplasia · Vulvar Intraepithelial Neoplasia (VIN)
Primary: Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples — 15.0; 37.5 percentage of…
N/A N=328 Diagnostic Accuracy of "Three Rings Vulvoscopy" for Detection of Vulvar Dermatosis
Lichen Sclerosus · Lichen Planus · Lichen Simplex Chronicus
Primary: Diagnostic Accuracy of "Three Rings Vulvoscopy" by the "Vulvoscopy Index" for Detection of Vulvar Dermatosis — 72; 0; 10; 246 Participants — p=0.6108
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
Phase 2 N=33 Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS)
Vulvar Lichen Sclerosus
Primary: Mean Change in Weekly Mean Worst Itch Numeric Rating Score (WI-NRS) — -4.0; -3.5 units on a scale
N/A N=30 Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy
Vulvovaginal Atrophy
Primary: The Main Outcome of the Study is the Efficacy of the Laser Procedure, Intended as the Amelioration of 50% of the Severity of the Vaginal Dryness at 12 Months, Compared…
N/A N=16 Suitability of DCE-MRI for Detection of Vascular Changes After VBT
Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus
Primary: Number of Participants With Adverse Events — 10 Participants
Phase 2 N=1 Salvage Ovarian FANG™ Vaccine + Carboplatinum
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression (TTP)
Phase 3 N=50 Therapy to Prevent Sexual Pain in Breast Cancer Survivors
Vulvodynia · Dyspareunia · Breast Cancer
Primary: Prevention of Entry Dyspareunia With Non-hormonal Therapy — 5.3; 1.04; NA; 0.57 Units on a scale — p=0.0149
N/A N=467 HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women
HIV-1 Infection
Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons
Early Phase 1 N=13 Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia
Cervical Intraepithelial Neoplasia Grade 2/3 · Cervical Squamous Cell Carcinoma In Situ · Cervical Squamous Intraepithelial Neoplasia 2
Primary: Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. — 4; 1…
Phase 2 N=33 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
Anal Cancer · Precancerous Condition
Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants
Phase 3 N=12,167 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
Cervical Cancer · Genital Warts
Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…
Phase 2 N=32 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients Completing the Protocol — 27 Participants
Phase 4 N=954 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Carcinoma, Basal Cell · Carcinoma, Squamous Cell · Skin Neoplasms
Primary: The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed — 3.37; 3.52 years — p=0.93
Phase 3 N=52 Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus
Vulvar Lichen Sclerosus
Primary: Change in SkinDEX-29 Score — -16.83; -5.92 score on a scale — p=0.007
Phase 2 N=33 Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
Leukoplakia, Oral
Primary: Best Overall Response Rate (BORR) — 36.4 percentage of participants
Phase 2 N=209 Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments
Vestibulodynia · Temporomandibular Disorder · Fibromyalgia Syndrome
Primary: Pain Score During the Tampon Test — 4.37; 3.75; 4.04; 4.36 score on a scale — p=0.3630
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
N/A N=33 HPV DNA Testing Through Mobile Mammography Unit
Cervical Cancer
Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants
Phase 2 N=21 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Cervical Cancer · Endometrial Cancer · Ovarian Cancer
Primary: Toxicity Rates of Patients Treated With Concurrent Avastin and Daily Pelvic Radiation With no Other Concurrent Chemotherapy — 766 Events
Phase 2 N=48 E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Papillomavirus Infections · Cervical Intraepithelial Neoplasia · Carcinoma In Situ
Primary: Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR) — 0; 5 Participants
Phase 2 N=29 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Cervical Cancer · Oropharyngeal Cancer · Vaginal Cancer
Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants
Phase 3 N=764 Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
Vulvovaginal Atrophy · Menopause · Dyspareunia
Primary: Co-Primary Efficacy Endpoint - Vaginal Superficial Cells — 17.50; 16.72; 23.20; 5.63 percentage of vaginal superficial cells — p=< 0.0001
N/A N=1,250 HPV-Based Screen-and-Treat Demonstration Project in Lilongwe
HPV Infection · Cervical Cancer · HIV Infections
Primary: Same-day Visual Inspection With Acetic Acid (VIA) Rate — 469; 459 Participants